Guardant Health, Inc. Common Stock
Symbol: GH (NASDAQ)
Company Description:
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
- Today's Open: $62.48
- Today's High: $63.575
- Today's Low: $61.633
- Today's Volume: 866.89K
- Yesterday Close: $62.48
- Yesterday High: $62.55
- Yesterday Low: $61.3165
- Yesterday Volume: 1.92M
- Last Min Volume: 743
- Last Min High: $62.528
- Last Min Low: $62.52
- Last Min VWAP: $62.52
- Name: Guardant Health, Inc. Common Stock
- Website: https://www.guardanthealth.com
- Listed Date: 2018-10-04
- Location: PALO ALTO, CA
- Market Status: Active
- CIK Number: 0001576280
- SIC Code: 8071
- SIC description: SERVICES-MEDICAL LABORATORIES
- Market Cap: $7.79B
- Round Lot: 100
- Outstanding Shares: 124.71M
- Asset Type: CS
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-26 | 4 | View |
| 2025-09-26 | 3 | View |
| 2025-09-24 | 8-K | View |
| 2025-09-18 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 144 | View |
| 2025-09-17 | 144 | View |
| 2025-09-15 | 4 | View |
| 2025-09-15 | 8-K | View |
| 2025-09-12 | 144 | View |
| 2025-09-11 | 4 | View |
| 2025-09-09 | 144 | View |
| 2025-09-03 | 4 | View |
| 2025-09-03 | 4 | View |